COVID-19 Impact on Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2020-2026

August 2020 | 134 pages | ID: C498EBD007C8EN
QYResearch

Abstracts

This report focuses on the global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Eli Lilly
• Pfizer
• Bayer
• Novartis AG
• Merck
• GlaxoSmithKline plc
• Roche
• AstraZeneca
• BaiYunShan General Factory
• SK Chemicals
• Teva Pharma
• Dong-A ST
• Metuchen Pharma
• Seoul Pharma
• Vectura Group

Market segment by Type, the product can be split into

• Sildenafil
• Tadalafil
• Avanafil
• Vardenafil

Market segment by Application, split into

• Hospital
• Retail Pharmacy
• Online Pharmacies
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players.
• To present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Phosphodiesterase Type 5 (PDE5) Inhibitor are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
1.4 Market Analysis by Type
  1.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Sildenafil
  1.4.3 Tadalafil
  1.4.4 Avanafil
  1.4.5 Vardenafil
1.5 Market by Application
  1.5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Retail Pharmacy
  1.5.4 Online Pharmacies
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Phosphodiesterase Type 5 (PDE5) Inhibitor Industry Impact
  1.6.1 How the Covid-19 is Affecting the Phosphodiesterase Type 5 (PDE5) Inhibitor Industry
    1.6.1.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Phosphodiesterase Type 5 (PDE5) Inhibitor Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Phosphodiesterase Type 5 (PDE5) Inhibitor Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Perspective (2015-2026)
2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions
  2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Share by Regions (2015-2020)
  2.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Strategy
  2.3.6 Primary Interviews with Key Phosphodiesterase Type 5 (PDE5) Inhibitor Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Market Size
  3.1.1 Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Revenue (2015-2020)
  3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Players (2015-2020)
  3.1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio
  3.2.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2019
3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
3.4 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
3.5 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Historic Market Size by Type (2015-2020)
4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Type (2021-2026)

5 PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITOR BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)
5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in North America (2019-2020)
6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
6.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Europe (2019-2020)
7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
7.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

8 CHINA

8.1 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in China (2019-2020)
8.3 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
8.4 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Japan (2019-2020)
9.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
9.4 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
10.4 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

11 INDIA

11.1 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in India (2019-2020)
11.3 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
11.4 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2015-2020)
12.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Central & South America (2019-2020)
12.3 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020)
12.4 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Eli Lilly
  13.1.1 Eli Lilly Company Details
  13.1.2 Eli Lilly Business Overview and Its Total Revenue
  13.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020))
  13.1.5 Eli Lilly Recent Development
13.2 Pfizer
  13.2.1 Pfizer Company Details
  13.2.2 Pfizer Business Overview and Its Total Revenue
  13.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.2.5 Pfizer Recent Development
13.3 Bayer
  13.3.1 Bayer Company Details
  13.3.2 Bayer Business Overview and Its Total Revenue
  13.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.3.5 Bayer Recent Development
13.4 Novartis AG
  13.4.1 Novartis AG Company Details
  13.4.2 Novartis AG Business Overview and Its Total Revenue
  13.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.4.5 Novartis AG Recent Development
13.5 Merck
  13.5.1 Merck Company Details
  13.5.2 Merck Business Overview and Its Total Revenue
  13.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.5.5 Merck Recent Development
13.6 GlaxoSmithKline plc
  13.6.1 GlaxoSmithKline plc Company Details
  13.6.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
  13.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.6.5 GlaxoSmithKline plc Recent Development
13.7 Roche
  13.7.1 Roche Company Details
  13.7.2 Roche Business Overview and Its Total Revenue
  13.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.7.5 Roche Recent Development
13.8 AstraZeneca
  13.8.1 AstraZeneca Company Details
  13.8.2 AstraZeneca Business Overview and Its Total Revenue
  13.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.8.5 AstraZeneca Recent Development
13.9 BaiYunShan General Factory
  13.9.1 BaiYunShan General Factory Company Details
  13.9.2 BaiYunShan General Factory Business Overview and Its Total Revenue
  13.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.9.5 BaiYunShan General Factory Recent Development
13.10 SK Chemicals
  13.10.1 SK Chemicals Company Details
  13.10.2 SK Chemicals Business Overview and Its Total Revenue
  13.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  13.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  13.10.5 SK Chemicals Recent Development
13.11 Teva Pharma
  10.11.1 Teva Pharma Company Details
  10.11.2 Teva Pharma Business Overview and Its Total Revenue
  10.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  10.11.4 Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  10.11.5 Teva Pharma Recent Development
13.12 Dong-A ST
  10.12.1 Dong-A ST Company Details
  10.12.2 Dong-A ST Business Overview and Its Total Revenue
  10.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  10.12.4 Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  10.12.5 Dong-A ST Recent Development
13.13 Metuchen Pharma
  10.13.1 Metuchen Pharma Company Details
  10.13.2 Metuchen Pharma Business Overview and Its Total Revenue
  10.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  10.13.4 Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  10.13.5 Metuchen Pharma Recent Development
13.14 Seoul Pharma
  10.14.1 Seoul Pharma Company Details
  10.14.2 Seoul Pharma Business Overview and Its Total Revenue
  10.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  10.14.4 Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  10.14.5 Seoul Pharma Recent Development
13.15 Vectura Group
  10.15.1 Vectura Group Company Details
  10.15.2 Vectura Group Business Overview and Its Total Revenue
  10.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
  10.15.4 Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
  10.15.5 Vectura Group Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Phosphodiesterase Type 5 (PDE5) Inhibitor Key Market Segments
Table 2. Key Players Covered: Ranking by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue
Table 3. Ranking of Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Sildenafil
Table 6. Key Players of Tadalafil
Table 7. Key Players of Avanafil
Table 8. Key Players of Vardenafil
Table 9. COVID-19 Impact Global Market: (Four Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Phosphodiesterase Type 5 (PDE5) Inhibitor Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Phosphodiesterase Type 5 (PDE5) Inhibitor Players to Combat Covid-19 Impact
Table 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2015-2020)
Table 18. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Growth Strategy
Table 24. Main Points Interviewed from Key Phosphodiesterase Type 5 (PDE5) Inhibitor Players
Table 25. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Players (2015-2020) (Million US$)
Table 26. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players (2015-2020)
Table 27. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2019)
Table 28. Global Phosphodiesterase Type 5 (PDE5) Inhibitor by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product Solution and Service
Table 31. Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 34. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Type (2015-2020)
Table 35. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type (2021-2026)
Table 36. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2015-2020)
Table 37. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 38. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Share by Application (2021-2026)
Table 39. North America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 41. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 42. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 43. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 44. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 45. Europe Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 47. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 49. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 51. China Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 52. China Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 53. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 54. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 55. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 56. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 57. Japan Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 59. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 61. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 65. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 67. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 69. India Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 70. India Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 71. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 72. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 73. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 74. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share (2019-2020)
Table 77. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type (2015-2020)
Table 79. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2015-2020)
Table 81. Eli Lilly Company Details
Table 82. Eli Lilly Business Overview
Table 83. Eli Lilly Product
Table 84. Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 85. Eli Lilly Recent Development
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer Product
Table 89. Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 90. Pfizer Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Product
Table 94. Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 95. Bayer Recent Development
Table 96. Novartis AG Company Details
Table 97. Novartis AG Business Overview
Table 98. Novartis AG Product
Table 99. Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 100. Novartis AG Recent Development
Table 101. Merck Company Details
Table 102. Merck Business Overview
Table 103. Merck Product
Table 104. Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 105. Merck Recent Development
Table 106. GlaxoSmithKline plc Company Details
Table 107. GlaxoSmithKline plc Business Overview
Table 108. GlaxoSmithKline plc Product
Table 109. GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 110. GlaxoSmithKline plc Recent Development
Table 111. Roche Company Details
Table 112. Roche Business Overview
Table 113. Roche Product
Table 114. Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 115. Roche Recent Development
Table 116. AstraZeneca Business Overview
Table 117. AstraZeneca Product
Table 118. AstraZeneca Company Details
Table 119. AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 120. AstraZeneca Recent Development
Table 121. BaiYunShan General Factory Company Details
Table 122. BaiYunShan General Factory Business Overview
Table 123. BaiYunShan General Factory Product
Table 124. BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 125. BaiYunShan General Factory Recent Development
Table 126. SK Chemicals Company Details
Table 127. SK Chemicals Business Overview
Table 128. SK Chemicals Product
Table 129. SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 130. SK Chemicals Recent Development
Table 131. Teva Pharma Company Details
Table 132. Teva Pharma Business Overview
Table 133. Teva Pharma Product
Table 134. Teva Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 135. Teva Pharma Recent Development
Table 136. Dong-A ST Company Details
Table 137. Dong-A ST Business Overview
Table 138. Dong-A ST Product
Table 139. Dong-A ST Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 140. Dong-A ST Recent Development
Table 141. Metuchen Pharma Company Details
Table 142. Metuchen Pharma Business Overview
Table 143. Metuchen Pharma Product
Table 144. Metuchen Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 145. Metuchen Pharma Recent Development
Table 146. Seoul Pharma Company Details
Table 147. Seoul Pharma Business Overview
Table 148. Seoul Pharma Product
Table 149. Seoul Pharma Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 150. Seoul Pharma Recent Development
Table 151. Vectura Group Company Details
Table 152. Vectura Group Business Overview
Table 153. Vectura Group Product
Table 154. Vectura Group Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020) (Million US$)
Table 155. Vectura Group Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Type: 2020 VS 2026
Figure 2. Sildenafil Features
Figure 3. Tadalafil Features
Figure 4. Avanafil Features
Figure 5. Vardenafil Features
Figure 6. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Other Case Studies
Figure 11. Phosphodiesterase Type 5 (PDE5) Inhibitor Report Years Considered
Figure 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions: 2020 VS 2026
Figure 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Players in 2019
Figure 17. Global Top Phosphodiesterase Type 5 (PDE5) Inhibitor Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue in 2019
Figure 19. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Eli Lilly Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 28. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Pfizer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 30. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Bayer Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 32. Novartis AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Novartis AG Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 34. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Merck Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 36. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. GlaxoSmithKline plc Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 38. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Roche Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 40. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. AstraZeneca Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 42. BaiYunShan General Factory Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. BaiYunShan General Factory Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 44. SK Chemicals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. SK Chemicals Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 46. Teva Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Teva Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 48. Dong-A ST Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Dong-A ST Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 50. Metuchen Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Metuchen Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 52. Seoul Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Seoul Pharma Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 54. Vectura Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Vectura Group Revenue Growth Rate in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2015-2020)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed